Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients

NCT01747980 is registered in ClinicalTrials.gov with Protalix as lead sponsor.

NCT NCT01747980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01747980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients
Lead sponsor
Protalix
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
March 31, 2014
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease